Galderma’s shares slumped the most in more than a year after US regulators turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.
Source link
Galderma’s shares slumped the most in more than a year after US regulators turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.
Source link